Home > Press > Nanotech Sciences Corp. Completes Capital Pool Company Initial Public Offering
Abstract:
Nanotech Sciences Corp. (the "Corporation"), a capital pool company, announced today that is has completed its initial public offering (the "Offering") by issuing 1,500,000 common shares at a price of $0.20 per common share, for gross proceeds to the Corporation of $300,000.
The common shares of the Corporation are expected to commence trading on the TSX Venture Exchange shortly under the trading symbol of "NAN.P".
Raymond James Ltd. (the "Agent") acted as agent for the Offering. In connection with the Offering, the Agent received an aggregate commission equal to 10% of the aggregate gross proceeds of the sale of the common shares. In addition, the Corporation granted to the Agent compensation options entitling the Agent to purchase up to 150,000 common shares at a price of $0.20 per common share for a period of 24 months from the date the Corporation's common shares are listed on the TSX Venture Exchange. The Agent also received a corporate finance fee.
The Corporation previously received gross proceeds of $100,000 from the sale of 1,000,000 common shares to its directors, officers and insiders (the "Founder's Shares") and $305,000 from the sale of 1,525,000 common shares (the "Private Placement") prior to the Offering.
The net proceeds of the Offering, the Private Placement and the Founder's Shares will be used by the Corporation to identify and evaluate assets or businesses for acquisition with a view to completing a "Qualifying Transaction" under the capital pool company program of the TSX Venture Exchange.
An aggregate of 1,100,000 of the previously issued and outstanding common shares of the Corporation were placed in escrow in accordance with the policies of the TSX Venture Exchange. An aggregate of 1,000,000 of the common shares are held by the Corporation's directors, officers and insiders and were issued at a price of $0.10 per common share for an aggregate purchase price of $100,000. 100,000 of the common shares are held by a member of the Pro Group (as defined in TSX Venture Exchange Policy 1.1) and were issued at a price of $0.20 per common share for an aggregate purchase price of $20,000.
Upon completion of the Offering, the Corporation granted a total of 402,500 stock options to its officers and directors. Each of the options is exercisable at a price of $0.20 per common share until February 8, 2011.
The directors and officers of the Corporation are Scott Walters, Director, President, Chief Executive Officer, Chief Financial Officer and Secretary; Jason Bullen, Director; and Bryce Bradley, Director.
For additional information, please see the Prospectus of the Corporation dated December 13, 2007.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.
####
Contacts:
Nanotech Sciences Corp.
Scott Walters
President and Chief Executive Officer
(416) 369-0374
(416) 369-0602 (FAX)
Copyright © Marketwire
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||